on Mainz BioMed N.V.
Mainz Biomed Launches Enhanced ColoAlert to Improve Screening Efficiency
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company, announced significant updates to its ColoAlert product on July 25, 2024. ColoAlert, a test for colorectal cancer (CRC), now features a novel DNA stabilizing buffer that accommodates varying sample volumes. This upgrade reduces the need for retesting, delivering screening outcomes within 2 - 3 days upon laboratory arrival.
The updated test, marketed across Europe and select international locations, uses proprietary methods to analyze cell DNA for tumor markers. Users benefit from an improved collection device, a new tube, and a tube holder, enhancing test usability and reliability.
"Our commitment to preserving DNA samples and optimizing testing procedures underscores our dedication to delivering superior colorectal cancer screening while ensuring convenience for patients," said Tarrin Khairi-Taraki, VP Commercial Operations.
The enhanced ColoAlert product is now available to current laboratory partners and prospective collaborators.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news